Email

yorations dgnize the To: Tara Schwetz @nih.gov> Subject: [EXTERNAL] Biotech Accelerator - potential NIH and ARPA-H collaborations CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and are confident the content is safe. Hi Tara, Congrats on your Acting Principal Deputy Director appointment! I spoke with Larry earlier today and he noted how pleased he was to have you working in this capacity. I had the chance to share with him a new venture that we've launched at the foundation and he recommended that I connect with you. I plan to do some targeted outreach in the DC area in the next couple of months and would love your perspectives before I start to initiate contact. Would you have time for a chat in the next week or two? Best, Jenni Jennifer Weisman, PhD Head of Strategic Alliances Biotech Accelerator @gatesfoundation.org BIO|NNOVATION ACCELERATOR A BILL@ MELINDA GATES foundation DISCLAIMER The information in this slide deck is provided for informational purposes only. Nothing contained in this slide deck is to be construed as, and no information contained herein may be used in connection with, any solicitation, recommendation or offer to buy or sell any security or any other product. Furthermore, no information contained herein should be regarded as a suggestion to engage in or refrain from any investment-related course of action. Note that name, branding, and identity are in development. Not for distribution 2 Gf ACCELERATOR TEAM LEADERSHIP JENNI WEISMAN, PHD HEAD OF STRATEGIC ALLIANCES Jenni leads the Partnerships Unit, focusing on strategic external alliances, internal partnerships, and portfolio management to enable the maximum leverage and capacity for the Accelerator's programmatic goals. She joined the Foundation after a decade of US Government service at NIH, HHS, and DARPA. Jenni is a physical chemist by training with antimalarial drug discovery experience. DAN WATTENDORF, MD DIRECTOR Dan is the Director of the Accelerator and leads the Activator Unit, focused on exploring and funding seedling efforts across a wide variety of topics for proof-of-concept potential. He joined the Foundation following a successful tenure at DARPA, where his funded technologies formed the basis of multiple mRNA, mAb, and cellular therapeutics companies. Dan is a clinically trained physician with multiple genetics fellowships and a retired USAF Colonel. Not for distribution MIKE MCCUNE, MD, PHD HEAD OF HIV FRONTIERS Mike leads the HIV Frontiers Unit, the flagship unit of the Accelerator that aims to discover, develop, and deliver cures for HIV and SCD for global implementation. He joined the foundation with over 30 years of research experience in HIV pathogenesis, prevention, and treatment. Mike is a physician scientist and co-founder of multiple companies in addition to his long and decorated career in academia. SUPPORT DEVELOPMENT OF DISRUPTIVE PLATFORMS BY ENABLING "MANY SHOTS ON GOAL" APPROACH Develop c / disruptive Oo platforms aN and ensure advancements benefit society at large yerage "ma goal" approach, Leverage "many shots on goal" approach partner network, and blended funding VISION STATEMENT: Fund the creation and development of new technological capabilities for broad societal benefit that are unaddressed in current government and private sector funding STRATEGIC APPROACH: Use portfolio approach to pursue "many shots on goal" for a given technology capability to reduce overall risk Collaborate with academia, commercial entities, philanthropic partners, government agencies, and more Leverage $50M annual grant fund + $50M annual equity fund + uniquely aligned syndicate partner funds Not for distribution 4 OUR VISION The overarching goal of the Accelerator is to foster platforms and capabilities that will eventually underpin future global health, agriculture, climate, and ecological interventions in support of the Foundation's mission. GLOBAL HEALTH + MORE Detect contagious people ? > ad e,2@ in the community ° Cure HIV with a single- Maintain and e r rn 2°